Anti-CD3 clinical trials in type 1 diabetes mellitus

AG Daifotis, S Koenig, L Chatenoud, KC Herold - Clinical immunology, 2013 - Elsevier
Two humanized, anti-CD3 mAbs with reduced FcR binding, teplizumab and otelixizumab,
have been evaluated in over 1500 subjects, ages 7–45, with new and recently diagnosed
T1D with a range of intravenous doses (3–48 mg) and regimens (6–14 days, single or
repeat courses). In general, studies that used adequate dosing demonstrated improvement
in stimulated C-peptide responses and reduced need for exogenous insulin for two years
and even longer after diagnosis. Drug treatment causes a transient reduction in circulating T …